The historical rank and industry rank for Precision BioSciences's Net Margin % or its related term are showing as below:
STU:PBS0'
s Net Margin % Range Over the Past 10 Years
Min: -448.86 Med: -325.45 Max: 10.43
Current: -96.73
STU:PBS0's Net Margin % is ranked worse than 51.01% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs STU:PBS0: -96.73
Precision BioSciences (STU:PBS0) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Precision BioSciences Net Margin % Related Terms
Precision BioSciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Precision BioSciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PBS0 vs TLSA, EQ, MIST: Net Margin % Comparison
For the Biotechnology subindustry, Precision BioSciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precision BioSciences (STU:PBS0) has a Net Margin % of -170.14% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Precision BioSciences and its competitors. According to the industry distribution chart, Precision BioSciences ranks #482 out of 945 companies in the Biotechnology industry, placing it in the top 51%.
Is Precision BioSciences' Net Margin % too high?
Precision BioSciences' current Net Margin % is -170.14%. Based on the distribution chart, Precision BioSciences ranks #482 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Precision BioSciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Net Margin % compare to TLSA and EQ?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #482 out of 945 companies for Net Margin %. This places Precision BioSciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current Net Margin % is -170.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (STU:PBS0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.52, compared to a current price of €6.06 — trading 298.7% above its estimated fair value. The current Net Margin % is -170.14%. Precision BioSciences' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Precision BioSciences (STU:PBS0), the current Net Margin % is -170.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (STU:PBS0) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of €6.06 is trading 298.7% above its estimated GF Value™ of €1.52.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for STU:PBS0:
Net Margin %: -170.14%
GF Value™: €1.52 vs. price of €6.06 (298.7% above fair value)
No single metric tells the full story. See the STU:PBS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
48GF Score
Get the complete analysis for STU:PBS0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PBS0 has been successfully added to your 
